Breaking News

Boehringer's AML Drug Gains Orphan Status

April 17, 2014

Volasertib being evaluated in patients with limited treatment options

Boehringer Ingelheim’s volasertib for acute myeloid leukemia (AML) has been granted Orphan Drug Designation by the FDA and European Commission. Volasertib is being evaluated in a Phase III trial for the treatment of patients aged 65 or older, with previously untreated AML, who are ineligible for intensive remission induction therapy.
 
Volasertib is an investigational compound that inhibits Plk1 enzymes, which regulates cell division and can result in prolonged cell cycle arrest, ultimately leading to cell death. AML is an aggressive cancer of the bone marrow and blood and has one of the lowest survival rates of all leukemias.
 
In both the U.S. and EU, Orphan Drug Designation is a status given to investigational compounds intended to treat a rare disease or condition that has limited treatment options.
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision